Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma.

Autor: Beird HC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Wu CC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nakazawa M; Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ingram D; Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Daniele JR; TRACTION Platform, Division of Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Lazcano R; Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Little L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Davies C; Research Department of Pathology, UCL Cancer Institute, London WC1E 6DD, UK., Daw NC; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Wani K; Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Wang WL; Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Gumbs C; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Rubin B; Institute Chair, Cleveland Clinic, Cleveland, OH 44195, USA., Conley A; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Flanagan AM; Research Department of Pathology, UCL Cancer Institute, London WC1E 6DD, UK.; Royal National Orthopaedic Hospital NHS Trust, Stanmore, Middlesex HA7 4LP, UK., Lazar AJ; Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Futreal PA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Publikováno v: HGG advances [HGG Adv] 2023 Jul 19; Vol. 4 (4), pp. 100224. Date of Electronic Publication: 2023 Jul 19 (Print Publication: 2023).

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.

Autor: Vellano CP; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., White MG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andrews MC; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Medicine, Central Clinical School, Monash University, Melbourne, Victoria, Australia., Chelvanambi M; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Witt RG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daniele JR; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Titus M; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McQuade JL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Conforti F; Division of Melanoma, Sarcomas, and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy., Burton EM; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lastrapes MJ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ologun G; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Surgery, Guthrie Courtland Medical Center, Courtland, NY, USA., Cogdill AP; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Immunai, New York, NY, USA., Morad G; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Prieto P; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Surgery, University of Rochester, Rochester, NY, USA., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Han G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khan MAW; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Helmink B; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Surgery, Washington University in St Louis, St Louis, MO, USA., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kovacs JJ; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Woodman SE; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Moffitt Cancer Center, Tampa, FL, USA., Peoples M; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cooper ZA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; AstraZeneca, Gaithersburg, MD, USA., Zhu H; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gao G; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Banerjee H; Clinical Development and Analytics, Novartis Pharmaceuticals, East Hanover, NJ, USA., Lau M; Novartis Pharma, Basel, Switzerland., Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lucci A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Keung EZ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ross MI; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pala L; Division of Melanoma, Sarcomas, and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy., Pagan E; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy., Segura RL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu Q; Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Borthwick MS; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lau E; Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Yates MS; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Westin SN; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wani K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tetzlaff MT; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Pathology, University of California, San Francisco, CA, USA., Haydu LE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahendra M; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ma X; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Logothetis C; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kulstad Z; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Johnson S; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hudgens CW; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Feng N; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Federico L; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Long GV; Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia., Futreal PA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Arur S; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moran AE; Cell, Development & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Wang L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Heffernan TP; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TPHeffernan@mdanderson.org., Marszalek JR; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrmarszalek@mdanderson.org., Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.

Publikováno v: Nature [Nature] 2022 Jun; Vol. 606 (7915), pp. 797-803. Date of Electronic Publication: 2022 Jun 15.

Adhesion-mediated mechanosignaling forces mitohormesis.

Autor: Tharp KM; Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA., Higuchi-Sanabria R; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, University of California Berkeley, Berkeley, CA 94597, USA., Timblin GA; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA 94720, USA., Ford B; Department of Nutritional Sciences and Toxicology, University of California Berkeley, Berkeley, CA 94720, USA; Novartis, Berkeley Center for Proteomics and Chemistry Technologies and Department of Chemistry, University of California Berkeley, Berkeley, CA 94720, USA., Garzon-Coral C; Chemical Engineering Department, Stanford University, Stanford, CA 94305, USA., Schneider C; Novartis, Berkeley Center for Proteomics and Chemistry Technologies and Department of Chemistry, University of California Berkeley, Berkeley, CA 94720, USA., Muncie JM; Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA., Stashko C; Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA., Daniele JR; MD Anderson Cancer Center, South Campus Research, Houston, CA 77054, USA., Moore AS; Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA., Frankino PA; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, University of California Berkeley, Berkeley, CA 94597, USA., Homentcovschi S; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, University of California Berkeley, Berkeley, CA 94597, USA., Manoli SS; Department of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA 94143, USA., Shao H; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA., Richards AL; Quantitative Biosciences Institute (QBI), J. David Gladstone Institutes, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA., Chen KH; Quantitative Biosciences Institute (QBI), J. David Gladstone Institutes, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA., Hoeve JT; UCLA Metabolomics Center, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA., Ku GM; Diabetes Center, Division of Endocrinology and Metabolism, Department of Medicine, UCSF, San Francisco, CA 94143, USA., Hellerstein M; Novartis, Berkeley Center for Proteomics and Chemistry Technologies and Department of Chemistry, University of California Berkeley, Berkeley, CA 94720, USA., Nomura DK; Department of Nutritional Sciences and Toxicology, University of California Berkeley, Berkeley, CA 94720, USA; Novartis, Berkeley Center for Proteomics and Chemistry Technologies and Department of Chemistry, University of California Berkeley, Berkeley, CA 94720, USA., Saijo K; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA 94720, USA., Gestwicki J; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA., Dunn AR; Department of Nutritional Sciences and Toxicology, University of California Berkeley, Berkeley, CA 94720, USA., Krogan NJ; Quantitative Biosciences Institute (QBI), J. David Gladstone Institutes, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA., Swaney DL; Quantitative Biosciences Institute (QBI), J. David Gladstone Institutes, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA., Dillin A; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, University of California Berkeley, Berkeley, CA 94597, USA., Weaver VM; Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Bioengineering and Therapeutic Sciences and Department of Radiation Oncology, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, and The Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: valerie.weaver@ucsf.edu.

Publikováno v: Cell metabolism [Cell Metab] 2021 Jul 06; Vol. 33 (7), pp. 1322-1341.e13. Date of Electronic Publication: 2021 May 20.

Divergent Nodes of Non-autonomous UPR ^ER Signaling through Serotonergic and Dopaminergic Neurons.

Autor: Higuchi-Sanabria R; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA., Durieux J; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA., Kelet N; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA., Homentcovschi S; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA., de Los Rios Rogers M; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA., Monshietehadi S; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA., Garcia G; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA., Dallarda S; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA., Daniele JR; TRACTION, The University of Texas MD Anderson Cancer Center, South Campus Research, Houston, TX 77054, USA., Ramachandran V; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA., Sahay A; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA., Tronnes SU; Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Boulder, CO 80309, USA., Joe L; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA., Dillin A; Department of Molecular & Cellular Biology, Howard Hughes Medical Institute, The University of California, Berkeley, Berkeley, CA 94720, USA. Electronic address: dillin@berkeley.edu.

Publikováno v: Cell reports [Cell Rep] 2020 Dec 08; Vol. 33 (10), pp. 108489.